Advertisement
Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Understanding Successful Compromise Standards to Cultivate Agreeable Connections - 2The most effective method to Pick The Right Speakers
- 3New ‘Cloud-9’ object could reveal the secrets of dark matter
- 4Polar bears are rewiring their own genetics to survive a warming climate
- 5Grasping the Course of Evacuation and Extradition in U.S. Migration
- Russian drone slams into block of flats in deadly wave of strikes across Kyiv
- One perk to marrying Richard Marx later in life? 'We don't have time' for stupid arguments, says Daisy Fuentes.
- How did I get my own unique set of fingerprints?
- Best Amusement Park Bite: What Do You Very much want to Crunch On?
- Extraordinary Miracles: The Cherished Islands for a Tropical Get-away
- Mickey Lee of 'Big Brother' fame dead at 35 after flu complications, family says
- NASA's Voyager 1 set to achieve historic distance from Earth
- Vote in favor of Your #1 4K television: Lucidity and Drenching Matter
- The most effective method to Beat Dental Tension and Guarantee Customary Exams
